Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26039080 | 0.75 | ADORA2A (0.36) | — | |
| SCHEMBL22143976 | 0.75 | PTGDR2 (0.45) | PTGDR2CA12CA1CA9HDAC6 | |
| SCHEMBL26039082 | 0.74 | DGAT1 (0.38) | — | |
| SCHEMBL26039079 | 0.73 | ADORA2A (0.35) | — | |
| SCHEMBL22143766 | 0.73 | PTGDR2 (0.43) | PTGDR2CA12CA1CA9HDAC6 | |
| SCHEMBL1593250 | 0.71 | MAPKAPK2 (0.38) | CA12CA1CA9HDAC6HDAC1 | |
| SCHEMBL22143612 | 0.70 | PTGDR2 (0.41) | PTGDR2HDAC6HDAC1HDAC3HDAC10 | |
| SCHEMBL29300790 | 0.69 | AAK1 (0.40) | PTGDR2LCK | |
| SCHEMBL22143628 | 0.69 | CYP17A1 (0.43) | PTGDR2CA12CA1CA9HDAC6 | |
| SCHEMBL11976697 | 0.69 | SLC22A12 (0.43) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164358-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | WO | disclosed |
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | PTGDR2 865/4885CA12 4771/4885CA1 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.